Jacobs to support construction of $1.2bn biotech manufacturing plant

Image courtesy of Jacobs

Jacobs originally supported the construction of the Holly Springs site, which broke ground in 2021. Now it is providing engineering, procurement and construction management services for the expansion, which involves construction of a large-scale cell culture contract manufacturing facility.

The facility will provide drug substance manufacturing, automated fill-finish and assembly, packaging and labelling services for global biopharmaceutical customers.

The expansion adds another eight 20,000-litre cell culture bioreactors and 400,000 square feet (37,161 square metres) of manufacturing space by 2028, in addition to the eight bioreactors for bulk drug substance already planned as part of the initial investment. That first phase of construction is planned for completion in 2025.

“Once complete, the site will be one of the largest, end-to-end cell culture contract manufacturing facilities in North America,” said Fujifilm Diosynth Biotechnologies chief operating officer and executive vice president of operations Kenneth Bilenberg.